Collectively, Exosome-CP exhibits remarkable advantages in targeting inflammatory endothelia and Mut-MSCs, providing a novel delivery platform for precision therapy in inflammation-related diseases and MPN models. Here, CP is linked to myeloproliferative neoplasm.